ELTP insider trading

OTC Markets OTCQB Healthcare

ELITE PHARMACEUTICALS INC /NV/ — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
85
Last 90 days
1
Buys / sells
2% / 19%
Market cap
$400.25M

About ELITE PHARMACEUTICALS INC /NV/

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Company website: www.elitepharma.com

ELTP insider activity at a glance

FilingIQ has scored 85 insider transactions for ELTP since Apr 29, 2013. The most recent filing in our index is dated Aug 19, 2026.

Across the full history, 2 open-market purchases and 16 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ELTP insider trades is 63.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest ELTP Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

Frequently asked

How many insider trades does FilingIQ track for ELTP?
FilingIQ tracks 85 Form 4 insider transactions for ELTP (ELITE PHARMACEUTICALS INC /NV/), covering filings from Apr 29, 2013 onwards. 1 of those were filed in the last 90 days.
Are ELTP insiders net buyers or net sellers?
Across the full Form 4 history for ELTP, 2 transactions (2%) were open-market purchases and 16 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ELTP insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ELTP in?
ELITE PHARMACEUTICALS INC /NV/ (ELTP) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $400.25M.

Methodology & sources

Every ELTP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.